Shirley J. Peters

机构：UCB Pharma (Belgium)

发表论文 11 篇 · 总被引 419 次 · h-index 9

代表论文

A CHO cell line engineered to express XBP1 and ERO1‐Lα has increased levels of transient protein expression (2013 · Biotechnology Progress · 被引 97)
The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation (2015 · Journal of Biological Chemistry · 被引 91)
Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions (2017 · Scientific Reports · 被引 52)
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies (2025 · mAbs · 被引 36)
Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability (2012 · Journal of Biological Chemistry · 被引 34)
Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions (2018 · Communications Biology · 被引 30)